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Definition   
Chronic Obstructive Pulmonary Disease (COPD)  is a 
type of lung disease by a decline in lung function over 
time in which subsets of patients may have dominant 
features of chronic bronchitis and/or emphysema 
characterized by long-term  airflow obstruction that is 
not fully reversible  with the main symptoms 
include shortness of breath and cough with sputum 
production typically worsens over time, some 
significant extra-pulmonary effects, and important 
comorbidities which may contribute to the severity of 
the disease in individual patients.  
http://www.who.int/respiratory/copd/GOLD_WR_06.pdf en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_diseas     
emedicine.medscape.com/article/297664-overview?pa=%2FOOPqamIew%2Fp1dAMq%2BJ7KjXjrTEuzO%2FMsNWCIiPMRs0neLeqn1hB%2BszABfchCz uV8SIvl8zjYv73GUyW5rsbWA%3D%3D#showall 
USMLE TEST 
A 50-year-old Caucasian male presents to the Emergency Department 
complaining of shortness of breath and unintentional weight loss over 
the past several months. On physical examination, the patient appears 
quite thin and breathes through pursed lips. Breath sounds are 
decreased in all lung fields. The patient's chest x-ray is provided in 
Figure A. Which of the following findings is expected on spirometry?   
1.  Increased FEV1  
2.  Decreased FEV1/FVC  
3.  Decreased TLC  
4.  Normal FEV1 but increased FVC  
5.  Normal lung values  
https://wire.ama-assn.org/education/usmle-step-2-prep-next-best-step-hypertension-and-shortness-breath 
USMLE TEST 
The correct answer is 2: The patient described above is suffering from 
Chronic Obstructive Pulmonary Disease (COPD), specifically 
emphysema. In emphysema, both FEV1 (forced expiratory volume in 1 
second) and FVC (forced vital capacity) are decreased, however, FEV1 is 
decreased more, therefore FEV1/FVC is decreased.  
Incorrect answers: 
 1 and 3: Both increased FEV1 and decreased TLC (total lung capacity) 
would be more consistent with a restrictive lung disease. 
4 and 5: Patients with COPD have a decreased FEV1 and a decreased 
FVC. 
https://wire.ama-assn.org/education/usmle-step-2-prep-next-best-step-hypertension-and-shortness-breath 
Epidemiology 1 
• Globally, as of 2010, COPD affected approximately 
329 million people (4.8% of the population) 
• In England, an estimated 0.84 million people (of 
50 million) have a diagnosis of COPD; this translates 
into approximately one person in 59 receiving a 
diagnosis of COPD at some point in their lives 
• In the United States approximately 6.3% of the 
adult population, totaling approximately 15 million 
people, have been diagnosed with COPD   
https://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_disease#Epidemiology 
Epidemiology 2 
• The disease affects men and women almost equally, 
as there has been increased tobacco use among 
women in the developed world 
• COPD is more common in older people  
• The number of deaths from COPD in 2012 became 
the third leading cause of death. 
https://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_disease#Epidemiology 
Epidemiology 
http://images.slideplayer.com/16/5124644/slides/slide_13.jpg 
COPD - Deaths / 1000 1990 Data projected to 2000. 
Epidemiology 
http://dm5migu4zj3pb.cloudfront.net/manuscripts/33000/33947/medium/JCI0833947.f2.jpg 
Chronic Obstructive Pulmonary Disease Among Adults 
Aged 18 and Over in the United States, 1998–2009. 
Risk Factors and Etiology     
• Smoking: smokers are 13 times more likely to die from the COPD 
• Air Pollution: indoor and outdoor pollutants 
• Occupational Dusts and Chemicals: industrial dust, chemicals, and 
gases 
• Genetics: in rare cases, genetic factors can cause people who have 
never smoked (a lack of the protein α1-antitrypsin (AAT), Salla 
disease, etc.) 
• Intravenous drug use: the pulmonary vascular damage that results 
from the insoluble filler contained in methadone or methylphenidate  
• Connective tissue disorders: Cutis laxa, Marfan syndrome, Ehlers-
Danlos syndrome, Vasculitis syndrome, etc.  
• Immunodeficiency syndromes 
• Age: incidence COPD increases with age.  
 
 
 
http://www.healthline.com/health/copd/risk-factors#Overview1 
Risk Factors and Etiology   
https://www.consumerhealthdigest.com/wp-content/uploads/2015/01/smoking-asthma.jpg 
Mechanism                                         
General 1 
• Pathologic changes in COPD occur in the large 
(central) airways, the small (peripheral) bronchioles, 
and the lung parenchyma 
• Most cases are the result of exposure to noxious 
stimuli, most often cigarette smoke 
• The normal inflammatory response is amplified in 
persons prone to COPD development  
• Increased numbers of activated polymorphonuclear 
leukocytes and macrophages release elastases, 
resulting in lung destruction   
 
http://emedicine.medscape.com/article/297664-overview?pa=%2FOOPqamIew%2Fp1dAMq%2BJ7KjXjrTEuzO%2FMsNWCIiPMRs0neLeqn1hB%2BszABfchCzuV8SIvl8zjYv73GUyW5rsbWA%3D%3D#a3 
Mechanism                                         
General 2 
• Accelerated aging and autoimmune mechanisms 
have also been proposed   
• Cigarette smoke causes neutrophil influx, which is 
required for the secretion of MMPs; this suggests, 
that neutrophils and macrophages are required for 
the development of emphysema  
• In addition to macrophages, T lymphocytes, 
particularly CD8+, play an important role in the 
pathogenesis of smoking-induced airflow limitation 
•    
http://emedicine.medscape.com/article/297664-overview?pa=%2FOOPqamIew%2Fp1dAMq%2BJ7KjXjrTEuzO%2FMsNWCIiPMRs0neLeqn1hB%2BszABfchCzuV8SIvl8zjYv73GUyW5rsbWA%3D%3D#a3 
Mechanism                                         
General 35 
• The dysregulation of apoptosis and defective 
clearance of apoptotic cells by macrophages play a 
prominent role in airway inflammation, particularly 
in emphysema  
• In patients with stable COPD without known 
cardiovascular disease, there is a high prevalence of 
microalbuminuria, which is associated with 
hypoxemia independent of other risk factors.  
http://emedicine.medscape.com/article/297664-overview?pa=%2FOOPqamIew%2Fp1dAMq%2BJ7KjXjrTEuzO%2FMsNWCIiPMRs0neLeqn1hB%2BszABfchCzuV8SIvl8zjYv73GUyW5rsbWA%3D%3D#a3 
Mechanism                                           
Schema 1  
Immunology of COPD  
http://www.nature.com/nri/journal/v8/n3/images/nri2254-f2.jpg 
Mechanism                                           
Schema 2 
Multifaceted mechanisms in COPD  
http://www.nature.com/nri/journal/v8/n3/images/nri2254-f2.jpg 
Mechanism                                         
Emphysema 1 
• Emphysema is a diagnosis defined by permanent 
enlargement of airspaces distal to the terminal 
bronchioles 
• This leads to a dramatic decline in the alveolar 
surface area available for gas exchange)  
http://emedicine.medscape.com/article/297664-overview?pa=%2FOOPqamIew%2Fp1dAMq%2BJ7KjXjrTEuzO%2FMsNWCIiPMRs0neLeqn1hB%2BszABfchCzuV8SIvl8zjYv73GUyW5rsbWA%3D%3D#a3 
Mechanism                                         
Emphysema 2 
• Loss of alveoli leads to airflow limitation by 2 
mechanisms: 1) loss of the alveolar walls results in a 
decrease in elastic recoil, which leads to airflow 
limitation, 2) loss of the alveolar supporting 
structure leads to airway narrowing, which further 
limits airflow  
• Emphysema has 3 morphologic patterns: 
centriacinar, panacinar, distal acinar (paraseptal)  
http://emedicine.medscape.com/article/297664-overview?pa=%2FOOPqamIew%2Fp1dAMq%2BJ7KjXjrTEuzO%2FMsNWCIiPMRs0neLeqn1hB%2BszABfchCzuV8SIvl8zjYv73GUyW5rsbWA%3D%3D#a3 
Mechanism                                         
Emphysema 3 
• Centriacinar emphysema is characterized by focal 
destruction limited to the respiratory bronchioles 
and the central portions of the acini  
• Panacinar emphysema involves the entire alveolus 
distal to the terminal bronchiole  
• Distal acinar emphysema is the least common form 
and involves distal airway structures, alveolar ducts, 
and sacs   
http://emedicine.medscape.com/article/297664-overview?pa=%2FOOPqamIew%2Fp1dAMq%2BJ7KjXjrTEuzO%2FMsNWCIiPMRs0neLeqn1hB%2BszABfchCzuV8SIvl8zjYv73GUyW5rsbWA%3D%3D#a3 
Mechanism                                         
Emphysema 4 
• The gradual destruction of alveolar septae and of 
the pulmonary capillary bed in emphysema leads to 
a decreased ability to oxygenate blood 
• The body compensates with lowered cardiac output 
and hyperventilation  
• Eventually, patients develop muscle wasting and 
weight loss and are identified as "pink puffers.“ 
http://emedicine.medscape.com/article/297664-overview?pa=%2FOOPqamIew%2Fp1dAMq%2BJ7KjXjrTEuzO%2FMsNWCIiPMRs0neLeqn1hB%2BszABfchCzuV8SIvl8zjYv73GUyW5rsbWA%3D%3D#a3 
USMLE TEST 
A 28-year-old patient presents to the hospital complaining of 
progressively worsening dyspnea and a dry cough. Radiographic imaging 
is shown below. Pulmonary function testing (PFT's) reveals a decreased 
FEV1 and FEV1/FVC, but an increase TLC. The patient states that he does 
not smoke. Which of the following conditions is most consistent with 
the patients symptoms?          
1.  Chronic bronchitis  
2.  Alpha1-antitrypsin deficiency  
3.  Pneumothorax  
4.  Asthma  
5.  Hypersensitivity pneumonitis  
https://wire.ama-assn.org/education/usmle-step-2-prep-next-best-step-hypertension-and-shortness-breath 
USMLE TEST 
The correct answer is 2: The patient presents with symptoms consistent 
with emphysema, and his young age of presentation and absent 
smoking history suggest it is due to genetic alpha1-antitrypsin 
deficiency.  
Incorrect answers: 
1: Though the spirometry values are consistent with an obstructive 
disease, chronic bronchitis is not consistent with the patient's other 
symptoms (lack of sputum, increased A-P diameter), 3: Pneumothorax, 
air within the pleural space, is not seen on the imaging provided and 
PFT's would likely show a decreased TLC if performed, 4: Though asthma 
is an obstructive disease, the patient's presentation is not consistent 
with an asthma exacerbation (wheezing, reversible nature, etc.), 5: 
Hypersensitivity pneumonitis would more commonly produce restrictive 
PFT values (normal/increased FEV1/FVC, decreased TLC). 
https://wire.ama-assn.org/education/usmle-step-2-prep-next-best-step-hypertension-and-shortness-breath 
Classification  
International Classification of Diseases   
https://www.tsoshop.co.uk/productimages/default.aspx?ISBN=9789241549165&FORMAT=3  http://apps.who.int/classifications/icd10/browse/2016/en#/XI 
• X Diseases of the respiratory system 
• Chronic lower respiratory diseases (J40-J47) 
• J40 Bronchitis, not specified as acute or chronic 
• J41 Simple and mucopurulent chronic bronchitis 
• J42 Unspecified chronic bronchitis 
• J43 Emphysema 
• J44 Other chronic obstructive pulmonary disease 
• J45 Asthma 
• J46 Status asthmaticus 
• J47 Bronchiectasis 
Classification                                         
GOLD staging of severity for COPD, based on the value of FEV1 
https://www.merckmanuals.com/professional/pulmonary-disorders/pneumonia/overview-of-pneumonia 
Stage I Mild COPD FEV1/FVC<0.70 FEV1≥ 80% normal 
Stage II Moderate 
COPD 
FEV1/FVC<0.70 FEV1 50-79% normal 
Stage III Severe COPD FEV1/FVC<0.70 FEV1 30-49% normal 
Stage IV Very Severe 
COPD 
FEV1/FVC<0.70 FEV1 <30% normal, or <50% 
normal with chronic 
respiratory failure present* 
* Usually, this means requiring long-term oxygen therapy. 
Classification                                 
Severity staging of airflow obstruction according to the 
American Thoracic Society (ATS)/European Respiratory 
Society (ERS) 
http://www.erswhitebook.org/chapters/chronic-obstructive-pulmonary-disease/ 
Mild FEV1/VC <5th percentile of predicted and FEV1 ≥70% pred 
Moderate FEV1/VC <5th percentile of predicted and FEV1 60–69% pred 
Moderately 
severe 
FEV1/VC <5th percentile of predicted and FEV1 50–59% pred 
Severe FEV1/VC <5th percentile of predicted and FEV1 35–49% pred 
Very severe FEV1/VC <5th percentile of predicted and FEV1 <35% pred 
FEV1: forced expiratory volume in 1 second; VC: vital capacity; % 
pred: % of predicted value; FVC: forced vital capacity. 
Symptoms and Signs 1 
• The most important symptoms of COPD are 
breathlessness on exertion and chronic cough with 
or without phlegm 
• The dyspnea usually worsens over time but is often 
not present in mild or moderate COPD 
• The cough may be dry or productive 
• Cough and phlegm often precede dyspnea on 
exertion by many years  
http://www.erswhitebook.org/chapters/chronic-obstructive-pulmonary-disease/ 
Symptoms and Signs 2 
• Other symptoms include wheezing and chest 
tightness 
• As the disease progresses and reaches the severe 
stages, fatigue, weight loss and anorexia may 
increase.  
http://www.erswhitebook.org/chapters/chronic-obstructive-pulmonary-disease/ 
Clinical Manifestations 1 
• A characteristic of COPD is exacerbations or 
episodes of acute worsening of the respiratory 
symptoms. 
• The most common causes of exacerbations are viral 
or bacterial infections 
• Increased air pollution also appears to precipitate 
exacerbations of COPD  
http://www.erswhitebook.org/chapters/chronic-obstructive-pulmonary-disease/ 
Clinical Manifestations 2 
• Some patients are particularly prone to 
exacerbations while others are not 
• Two or more exacerbations during the previous year 
is the most important indicator of a future 
exacerbation.  
http://www.erswhitebook.org/chapters/chronic-obstructive-pulmonary-disease/ 
Clinical Manifestations 3 
• Exacerbations accelerate the decline in lung 
function that characterises COPD, resulting in 
reduced physical activity, poorer quality of life, and 
an increased risk of death; they are also responsible 
for a large proportion of the healthcare costs 
attributable to COPD  
• Patients with COPD often suffer from other diseases 
(comorbidities)   
http://www.erswhitebook.org/chapters/chronic-obstructive-pulmonary-disease/ 
Clinical Manifestations 4 
• The comorbidities may share common risk factors 
with COPD, in particular cigarette smoking, and may 
also represent extrapulmonary manifestations or 
complications of COPD, such as muscle dysfunction 
due to inactivity 
• Comorbidities may be secondary to treatment of 
COPD; for example, osteoporosis due to oral 
corticosteroid treatment.  
http://www.erswhitebook.org/chapters/chronic-obstructive-pulmonary-disease/ 
Clinical Manifestations 5 
• The most common comorbidities in COPD are 
ischemic heart disease, anxiety and depression, 
osteoporosis, skeletal muscle dysfunction, gastro-
esophageal reflux, anaemia, lung cancer, diabetes 
and metabolic syndrome 
• Comorbidities contribute to the overall severity and 
manifestations of the disease and can occur in mild, 
moderate or severe COPD    
http://www.erswhitebook.org/chapters/chronic-obstructive-pulmonary-disease/ 
Clinical Manifestations 6 
• The clinical effects of COPD show considerable 
inter-individual variation, depending on which 
respiratory symptoms predominate, the frequency 
of exacerbations, the level and rate of lung function 
decline and the amount of emphysema, as well as 
comorbidities. 
• Various subtypes of the disease are often termed 
phenotypes of COPD. 
http://www.erswhitebook.org/chapters/chronic-obstructive-pulmonary-disease/ 
USMLE TEST 
A patient with a1-antitrypsin deficiency is warned by his physician that 
his increasing dyspnea may be worsened by his continued cigarette 
smoking. Which of the following factors, released by both neutrophils 
and alveolar macrophages, is responsible for the patient's condition?   
1.  Major Basic Protein  
2.  Antibodies against alpha-3 segment of collagen IV (COL4A3)  
3.  Mucus  
4.  Surfactant  
5.  Elastase  
https://wire.ama-assn.org/education/usmle-step-2-prep-next-best-step-hypertension-and-shortness-breath 
USMLE TEST 
The correct answer is 5: The patient is suffering from emphysema 
caused by his genetic disorder, a1-antitrypsin deficiency. This condition 
can be worsened by smoking-mediated increased release of elastase 
from macrophages and neutrophils. 
Incorrect answers: 
1: Major basic protein is secreted by eosinophils. 
2: Antibodies (secreted by B-cells) against type IV collagen is seen with 
Goodpasture syndrome. 
3: Mucus is produced by mucous glands in the submucosa as well as by 
goblet cells. 
4: Surfactant is produced by type II pneumocytes. 
https://wire.ama-assn.org/education/usmle-step-2-prep-next-best-step-hypertension-and-shortness-breath 
Complications 
http://www.healthline.com/health/copd/serious-complications#Complications2 
• Pneumonia 
• COPD heart failure (Cor pulmonale) 
• Lung cancer 
• Diabetes 
• Dementia 
• Arrhythmias 
• Osteoporosis 
• Respiratory failure.  
Diagnosis   
• The diagnosis of COPD should be considered in 
anyone over the age of 35 to 40 who has shortness 
of breath, a chronic cough, sputum production, or 
frequent winter colds and a history of exposure to 
risk factors for the disease 
• The formal diagnosis of COPD is made, when the 
ratio of forced expiratory volume in 1 second over 
forced vital capacity (FEV1/FVC) is less than 70% of 
that predicted for a matched control  
• Screening those without symptoms is not 
recommended.  
https://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_disease#Signs_and_symptoms 
Diagnosis                                             
Spirometry 1 
http://www.medscape.org/viewarticle/741196 
PEFR = peak expiratory flow rate; TLC = total lung 
capacity. 
Diagnosis                                             
Spirometry 2 
http://image.slidesharecdn.com/copyofslsqasthmamanagementpptv050811piccomp-141113083910-conversion-gate02/95/spirometry-basics-2-30-638.jpg?cb=1415868230 
Diagnosis                                             
Spirometry 3 
http://a360-wp-uploads.s3.amazonaws.com/wp-content/uploads/rtmagazi/2011/10/10-01_02.jpg 
Diagnosis                                            
Arterial Blood Gas (ABG) Findings   
• Patients with mild COPD have mild to moderate 
hypoxemia without hypercapnia 
• As the disease progresses, hypoxemia worsens and 
hypercapnia may develop, with the latter commonly 
being observed as the FEV 1 falls below 1 L/s or 30% 
of the predicted value  
• pH usually is near normal; a pH below 7.3 generally 
indicates acute respiratory compromise 
• Chronic respiratory acidosis leads to compensatory 
metabolic alkalosis. 
 
http://emedicine.medscape.com/article/297664-overview?pa=P4tWSkqAfuEbVp94c%2FW11%2B%2Fk7GZhKH%2B3snXYEMg6JZjYixQ%2FuxvzKUqypCxZhb0X8SIvl8zjYv73GUyW5rsbWA%3D%3D#a1 
Diagnosis                                             
Frontal And Lateral Chest Radiographs  
• Flattening of the diaphragm 
• Increased retrosternal air space 
• A long, narrow heart shadow 
• Rapidly tapering vascular shadows accompanied by 
hyperlucency of the lungs 
• Radiographs in patients with chronic bronchitis 
show increased bronchovascular markings and 
cardiomegaly. 
http://emedicine.medscape.com/article/297664-overview?pa=P4tWSkqAfuEbVp94c%2FW11%2B%2Fk7GZhKH%2B3snXYEMg6JZjYixQ%2FuxvzKUqypCxZhb0X8SIvl8zjYv73GUyW5rsbWA%3D%3D#a1 
Diagnosis                                             
Imaging Studies  1 
https://images.radiopaedia.org/images/266487/d35992af9e42aba7d71001c13843c3_jumbo.jpg 
Diagnosis                                             
Imaging Studies  2 
http://thoracicandsleep.com.au/wp-content/uploads/2015/10/copd-medical-imaging.jpg 
Diagnosis                                              
High-Resolution Computed Tomography  
• Greater sensitivity than standard chest radiography 
• High specificity for diagnosing emphysema 
(outlined bullae are not always visible on a 
radiograph) 
• May provide an adjunctive means of diagnosing 
various forms of COPD (e.g., lower lobe disease may 
suggest alpha1-antitrypsin (AAT) deficiency 
• May help the clinician determine whether surgical 
intervention would benefit the patient. 
http://emedicine.medscape.com/article/297664-overview?pa=P4tWSkqAfuEbVp94c%2FW11%2B%2Fk7GZhKH%2B3snXYEMg6JZjYixQ%2FuxvzKUqypCxZhb0X8SIvl8zjYv73GUyW5rsbWA%3D%3D#a1 
Diagnosis                                             
Imaging Studies  3 
https://images.radiopaedia.org/images/266487/d35992af9e42aba7d71001c13843c3_jumbo.jpg 
Diagnosis                                             
Imaging Studies  4 
http://www.radiologyassistant.nl/data/bin/w440/a5097977c9caf7_rb1.jpg 
Diagnosis                                              
Other Tests 1   
• Hematocrit  (patients with polycythemia) 
• Serum potassium (diuretics, beta-adrenergic 
agonists, and theophylline act to lower potassium 
levels) 
• Measure AAT in patients  < 40 years or with a family 
history of emphysema at an early age 
• Sputum evaluation (a transformation from mucoid 
in stable chronic bronchitis to purulent in acute 
exacerbations) . 
http://emedicine.medscape.com/article/297664-overview?pa=P4tWSkqAfuEbVp94c%2FW11%2B%2Fk7GZhKH%2B3snXYEMg6JZjYixQ%2FuxvzKUqypCxZhb0X8SIvl8zjYv73GUyW5rsbWA%3D%3D#a1 
Diagnosis                                              
Other Tests 2  
• Pulse oximetry provides instant feedback on a 
patient's status 
• Electrocardiography can establish that hypoxia is 
not cardiac 
• The distance walked in 6 minutes is a predictor of 
mortality in patients with moderate COPD 
• Right-sided heart catheterization can confirm 
pulmonary artery hypertension. 
http://emedicine.medscape.com/article/297664-overview?pa=P4tWSkqAfuEbVp94c%2FW11%2B%2Fk7GZhKH%2B3snXYEMg6JZjYixQ%2FuxvzKUqypCxZhb0X8SIvl8zjYv73GUyW5rsbWA%3D%3D#a1 
USMLE TEST 
A 60-year-old male presents to your office complaining of dyspnea on 
exertion. He reports smoking two packs of cigarettes per day for the 
past 25 years. A lung CT is shown in Figure A. Which of the following is 
LEAST likely to be involved in the pathogenesis of this patient's disease?  
1.  Immunoglobulin A  
2.  Proteinase 3  
3.  Neutrophil elastase  
4.  Proteases released by macrophages  
5.  Matrix metalloproteinases  
 
https://wire.ama-assn.org/education/usmle-step-2-prep-next-best-step-hypertension-and-shortness-breath 
USMLE TEST 
The correct answer is 1: This patient most likely has centriacinar 
emphysema. Enlarged airspaces can be seen on CT, contributing to the 
diagnosis. IgA does not play a role in the development of emphysema. 
Incorrect answers: 
2- 5: All of the above items are normally implicated in the pathogenesis 
of emphysema through their functions in lung parenchymal breakdown 
or remodeling. 
https://wire.ama-assn.org/education/usmle-step-2-prep-next-best-step-hypertension-and-shortness-breath 
Diagnosis                                              
Differentiation     
http://patient.info/doctor/chronic-obstructive-pulmonary-disease-pro 
• Asthma: diagnosed by establishing reversibility or 
variability of airflow obstruction either by 
spirometry or peak flow measurements after 
treatment with a bronchodilator or steroid  
• Other diagnoses to consider are congestive heart 
failure, bronchiectasis, allergic fibrosing alveolitis, 
pneumoconiosis, asbestosis or other restrictive lung 
conditions, tuberculosis, lung cancer, obliterative 
bronchiolitis, bronchopulmonary dysplasia, 
anaemia or generally poor physical condition. 
Management 1 
• Assessment and monitoring of disease, reduction of 
risk factors, management of stable COPD, 
management of exacerbations 
• The goals of management are to relieve symptoms, 
prevent disease progression, improve exercise 
tolerance, improve health status, prevent and treat 
complications and exacerbations, reduce mortality 
and prevent or minimize side-effects from treatment   
http://www.erswhitebook.org/chapters/chronic-obstructive-pulmonary-disease/ 
Management 2 
• Important components of management are smoking 
cessation, medical treatment with bronchodilators 
as well as inhibitors of inflammation, physical 
exercise and, in advanced disease, oxygen therapy, 
influenza vaccination once a year, pneumococcal 
vaccination once every 5 years 
• Pulmonary rehabilitation is important, the most 
effective component of pulmonary rehabilitation is 
physical exercise.  
http://www.erswhitebook.org/chapters/chronic-obstructive-pulmonary-disease/ 
Management                                     
Approaches to Management by COPD Stage 1  
• Stage I (mild obstruction): short-acting 
bronchodilator as needed 
• Stage II (moderate obstruction): short-acting 
bronchodilator as needed; long-acting 
bronchodilator(s); cardiopulmonary rehabilitation 
• Stage III (severe obstruction): short-acting 
bronchodilator as needed; long-acting 
bronchodilator(s); cardiopulmonary rehabilitation; 
inhaled glucocorticoids if repeated exacerbations  
http://emedicine.medscape.com/article/297664-overview?pa=P4tWSkqAfuEbVp94c%2FW11%2B%2Fk7GZhKH%2B3snXYEMg6JZjYixQ%2FuxvzKUqypCxZhb0X8SIvl8zjYv73GUyW5rsbWA%3D%3D#a1 
Management                                     
Approaches to Management by COPD Stage 2 
• Stage IV (very severe obstruction or moderate 
obstruction with evidence of chronic respiratory 
failure): short-acting bronchodilator as needed; 
long-acting bronchodilator(s); cardiopulmonary 
rehabilitation; inhaled glucocorticoids if repeated 
exacerbation; long-term oxygen therapy (if criteria 
met); consider surgical options such as lung volume 
reduction surgery (LVRS) and lung transplantation. 
http://emedicine.medscape.com/article/297664-overview?pa=P4tWSkqAfuEbVp94c%2FW11%2B%2Fk7GZhKH%2B3snXYEMg6JZjYixQ%2FuxvzKUqypCxZhb0X8SIvl8zjYv73GUyW5rsbWA%3D%3D#a1 
Management                                     
Medications  1 
• Short-acting beta 2 -agonist bronchodilators (e.g., 
albuterol, metaproterenol, levalbuterol, pirbuterol) 
• Long-acting beta 2 -agonist bronchodilators (e.g., 
salmeterol, formoterol, arformoterol, indacaterol, 
vilanterol) 
• Respiratory anticholinergics (e.g., ipratropium, 
tiotropium, aclidinium) 
• Xanthine derivatives (i.e., theophylline) 
• Phosphodiesterase-4 Inhibitors (i.e., roflumilast)  
http://emedicine.medscape.com/article/297664-overview?pa=P4tWSkqAfuEbVp94c%2FW11%2B%2Fk7GZhKH%2B3snXYEMg6JZjYixQ%2FuxvzKUqypCxZhb0X8SIvl8zjYv73GUyW5rsbWA%3D%3D#a1 
Management                                     
Medications  2 
• Inhaled corticosteroids (e.g., fluticasone, 
budesonide) 
• Oral corticosteroids (e.g., prednisone) 
• Beta 2 -agonist and anticholinergic combinations 
(e.g., ipratropium and albuterol, umeclidinium 
bromide/vilanterol inhaled) 
• Beta 2 -agonist and corticosteroid combinations 
(e.g., budesonide/formoterol, fluticasone and 
salmeterol). 
http://emedicine.medscape.com/article/297664-overview?pa=P4tWSkqAfuEbVp94c%2FW11%2B%2Fk7GZhKH%2B3snXYEMg6JZjYixQ%2FuxvzKUqypCxZhb0X8SIvl8zjYv73GUyW5rsbWA%3D%3D#a1 
Management                                     
Bronchodilators 1 
• Inhaled bronchodilators are the primary 
medications used and result in a small overall 
benefit 
• There are two major 
types, β2agonists and anticholinergics; both exist in 
long-acting and short-acting forms 
• Short-acting agents are recommended on an as 
needed basis 
• In those with more severe disease, long-acting 
agents are recommended  
https://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_disease#Management 
Management                                     
Bronchodilators 2 
• If long-acting bronchodilators are insufficient, then 
inhaled corticosteroids are typically added 
• With respect to long-acting agents, it is unclear 
if tiotropium (a long-acting anticholinergic) or long-
acting beta agonists (LABAs) are better, and it may 
be worth trying each and continuing the one that 
worked best   
https://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_disease#Management 
Management                                     
Bronchodilators 3 
• There are several short-acting β2 agonists available 
including salbutamol and terbutaline; they provide 
some relief of symptoms for four to six hours 
• Long-acting β2 agonists such 
as salmeterol and formoterol are often used as 
maintenance therapy; when used with inhaled 
steroids they increase the risk of pneumonia 
• There are two main anticholinergics used in COPD, 
ipratropium and tiotropium; ipratropium is a short-
acting agent while tiotropium is long-acting  
https://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_disease#Management 
Management                                     
Bronchodilators 4 
• Anticholinergics can cause dry mouth and urinary 
tract symptoms ND are also associated with 
increased risk of heart disease and stroke 
• Aclidinium, another long acting agent which came to 
market in 2012, has been used as an alternative to 
tiotropium. 
https://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_disease#Management 
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Corticosteroids 1 
• Corticosteroids are usually used in inhaled form but 
may also be used as tablets to treat and prevent 
acute exacerbations 
• While inhaled corticosteroids (ICS) have not shown 
benefit for people with mild COPD, they decrease 
acute exacerbations in those with either moderate 
or severe disease 
• By themselves ICS have no effect on overall one-year 
mortality  
https://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_disease#Management 
Management                                     
Corticosteroids 2 
• When used in combination with a LABAs they may 
decrease mortality compared to either ICS or LABAs 
alone 
• Inhaled steroids are associated with increased rates 
of pneumonia 
• Long-term treatment with steroid tablets is 
associated with significant side effects. 
https://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_disease#Management 
Management                                        
Other medication 1 
• Long-term antibiotics, specifically those from 
the macrolide class such as erythromycin, reduce 
the frequency of exacerbations in those who have 
two or more a year 
• This practice may be cost effective in some areas of 
the world 
• Concerns include that of antibiotic resistance and 
hearing problems with azithromycin  
https://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_disease#Management 
Management                                        
Other medication 2 
• Methylxanthines such as theophylline generally 
cause more harm than benefit and thus are usually 
not recommended, but may be used as a second-
line agent in those not controlled by other measures 
• Mucolytics may help to reduce exacerbations in 
some people with chronic bronchitis 
• Cough medicines are not recommended. 
https://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_disease#Management 
USMLE TEST 
A 65-year-old male presented to his primary care physician with 
exertional dyspnea. The patient had a 30-year history of smoking one 
pack of cigarettes per day. Physical examination reveals a barrel-chested 
appearance, and it is noted that the patient breathes through pursed 
lips. Spirometry shows decreased FEV1, FVC, and FEV1/FVC. This 
patient’s upper lobes are most likely to demonstrate which of the 
following?  
1.  Panacinar emphysema  
2.  Centriacinar emphysema  
3.  Calcified nodule  
4.  Hypersensitivity pneumonitis  
5.  Uncalcified nodule  
https://wire.ama-assn.org/education/usmle-step-2-prep-next-best-step-hypertension-and-shortness-breath 
USMLE TEST 
The correct answer is 2: This clinical presentation is consistent with 
centriacinar emphysema, which is typically found in patients suffering 
from COPD as a result of long-term cigarette smoking.  
Incorrect answers: 
1: Panacinar emphysema is most commonly the result of alpha-1-
antitrypsin deficiency rather than chronic smoking. 
3 & 5: A pulmonary lung nodule raises suspicion for cancer, granuloma, 
fungal infection, or a number of other conditions. A calcified nodule is 
more likely to be the result of a granuloma resulting from a disease such 
as previous fungal infection, while a spiculated uncalcified nodule is 
suspicious for lung cancer or a metastasis. 
4: The incidence of hypersensitivity pneumonitis in smokers is actually 
less than non-smokers. This pattern would not be expected in an 
emphysematous patient. 
https://wire.ama-assn.org/education/usmle-step-2-prep-next-best-step-hypertension-and-shortness-breath 
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Oxygen 1 
• Supplemental oxygen is recommended in those with 
low oxygen levels at rest (a partial pressure of 
oxygen of less than 50–55 mmHg or oxygen 
saturations of less than 88%) 
• In those with normal or mildly low oxygen levels, 
oxygen supplementation may improve shortness of 
breath 
• There is a risk of fires and little benefit when those 
on oxygen continue to smoke  
https://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_disease#Management 
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Oxygen 2 
• During acute exacerbations, many require oxygen 
therapy; the use of high concentrations of oxygen 
without taking into account a person's oxygen 
saturations may lead to increased levels of carbon 
dioxide and worsened outcomes 
• In those at high risk of high carbon dioxide levels, 
oxygen saturations of 88–92% are recommended, 
while for those without this risk recommended 
levels are 94–98%. 
https://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_disease#Management 
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Exacerbations 1 
• Acute exacerbations are typically treated by 
increasing the use of short-acting bronchodilators; 
this commonly includes a combination of a short-
acting inhaled beta agonist and anticholinergic 
• These medications can be given either via 
a metered-dose inhaler with a spacer or via 
a nebulizer with both appearing to be equally 
effective 
• Nebulization may be easier for those who are more 
unwell   
https://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_disease#Management 
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Exacerbations 2 
• Oral corticosteroids improve the chance of recovery 
and decrease the duration of symptoms; 5 days of 
steroids work as well as 10 - 14. 
•  In those with a severe exacerbation, antibiotics 
improve outcomes 
( amoxicillin, doxycycline and azithromycin) 
• The FDA recommends against the use 
of fluoroquinolones when other options are 
available due to higher risks of serious side effects   
https://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_disease#Management 
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Exacerbations 3 
• There is no clear evidence for those with less severe 
cases 
• For those with respiratory failure with acutely raised 
CO2 levels non-invasive positive pressure 
ventilation decreases the probability of death or the 
need of intensive care admission 
• Additionally, theophylline may have a role in those 
who do not respond to other measures  
https://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_disease#Management 
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Exacerbations 4 
• Fewer than 20% of exacerbations require hospital 
admission 
• In those without acidosis from respiratory 
failure, home care ("hospital at home") may be able 
to help avoid some admissions. 
https://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_disease#Management 
Management                                        
Nebulizers and Spacers 
Nebulizer 
http://apqualitycare.com/product/nebulizers-spacers/ 
Spacer 
Management                                        
Surgery   
• For those with very severe disease, surgery is 
sometimes helpful and may include lung 
transplantation or lung volume reduction surgery 
• Lung volume reduction surgery involves removing 
the parts of the lung most damaged by emphysema 
allowing the remaining, relatively good lung to 
expand and work better  
https://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_disease#Management 
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Pulmonary Rehabilitation 
• Patient and family education 
• Smoking cessation 
• Medical management (including oxygen and 
immunization) 
• Respiratory and chest physiotherapy 
• Physical therapy with bronchopulmonary hygiene, 
exercise, and vocational rehabilitation 
• Psychosocial support. 
http://emedicine.medscape.com/article/297664-overview?pa=P4tWSkqAfuEbVp94c%2FW11%2B%2Fk7GZhKH%2B3snXYEMg6JZjYixQ%2FuxvzKUqypCxZhb0X8SIvl8zjYv73GUyW5rsbWA%3D%3D#a1 
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Patient Education 
• It is important to educate the patient with COPD 
about the disease and to encourage his or her active 
participation in therapy 
• The 2 most essential points for the patient to 
understand are as follows: 
• The dangers of smoking and the improvement in 
quality of life attainable with smoking cessation 
• The need to seek medical care early during an 
exacerbation and to not wait until they are in 
distress. 
http://emedicine.medscape.com/article/297664-overview?pa=P4tWSkqAfuEbVp94c%2FW11%2B%2Fk7GZhKH%2B3snXYEMg6JZjYixQ%2FuxvzKUqypCxZhb0X8SIvl8zjYv73GUyW5rsbWA%3D%3D#a1 
Prognosis 1 
 
• COPD is a chronic, progressive disease showing 
great variation in its natural history 
• Spirometry providing data on FEV 1 and FVC is the 
most common measure of disease progression 
• A large cohort of patients with COPD of GOLD stage 
II+ followed up every 6 months for 3 years showed a 
mean annual decline in FEV 1 of 33 mL 
• An annual decline in FEV 1 >40 mL was seen in 38% 
of the patients, while 8% showed an average annual 
increase of 20 mL  
http://www.erswhitebook.org/chapters/chronic-obstructive-pulmonary-disease/ 
Prognosis 2 
 
• Current smoking and emphysema are related to 
more rapid decline in FEV 1 . 
• Factors that indicate a poor prognosis are frequent 
exacerbations, respiratory insufficiency, nutritional 
status and comorbidities.  
http://www.erswhitebook.org/chapters/chronic-obstructive-pulmonary-disease/ 
Prophylaxis 1 
• Identification and reduction of exposure to risk 
factors are important steps in the prevention and 
treatment of COPD 
• All individuals who smoke should be encouraged to 
quit regardless of their disease status 
• Smokers without COPD should be offered smoking-
cessation advice  
• Preventing passive smoking in fetal and early life is 
important to reduce the risk of COPD in adult life  
http://www.erswhitebook.org/chapters/chronic-obstructive-pulmonary-disease/ 
Prophylaxis 2 
• Reduction of exposure to smoke from indoor 
biomass combustion, particularly among women 
and children, is important to reduce the prevalence 
of COPD  
• Prevention of COPD exacerbations is important: 
influenza and pneumococcal vaccination as well as 
treatment with inhaled long-acting bronchodilators 
and inhaled corticosteroids all work to reduce 
exacerbations and hospitalisations for COPD. 
http://www.erswhitebook.org/chapters/chronic-obstructive-pulmonary-disease/ 
Abbreviations  
AAT -protein α1-antitrypsin 
ABG - Arterial Blood Gas  
COPD - Chronic Obstructive Pulmonary Disease 
FEV1  - forced expiratory volume in 1 second 
ICS -inhaled corticosteroids  
LABAs - long-acting beta agonists  
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